IL17A and psoriasis: In imiquimod-induced psoriasis, PARP1 showed an anti-inflammatory action, and its PARP1−/− mice model in genetic deletion exacerbated symptoms by increasing the secretion of cytokines IL-6, IL-17, and IL-23 [103].